ADAC's stock jumps after Q1 report
ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine
ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine vendor'sstock up 19% to close at $14.13 a share on Jan. 10, a 52-weekhigh.
ADAC said that it expects first-quarter revenues of $54 millionto $55 million, a 24% increase over last year's sales of $44 million.Earnings per share will be about 20¢ versus 15¢ in thesame period last year. Nuclear medicine bookings skyrocketed 61%to $48 million.
In a presentation last week at the Hambrecht & Quist HealthCare Conference in San Francisco, ADAC CEO David Lowe said thecompany's Molecular Coincidence Detection (MCD) technology isdriving new sales and will enable the company to take market sharefrom other vendors and other modalities.
"Over time, (MCD) has the potential not only to improveour market share in our core business, but more importantly todrive additional market opportunities for our core business aswe replace conventional imaging in the staging of cancer patients,"Lowe said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
